Meeder Asset Management’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

Meeder Asset Management’s Portfolio RARX Stock Details RARX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-6,209	Closed	-$147K	–	2514
2019 Q3	$147K	Buy	6,209 +1,290	+26%	+$38.2K	0.01%	690
2019 Q2	$147K	Hold	4,919	–	–	0.01%	655
2019 Q1	$111K	Sell	4,919 -392	-7%	-$8.43K	0.01%	679
2018 Q4	$96K	Buy	5,311 +2,049	+63%	+$32.2K	0.01%	647
2018 Q3	$60K	Buy	+3,262	New	+$38.7K	﹤0.01%	749
2018 Q2	–	Sell	-237	Closed	-$1K	–	1749
2018 Q1	$1K	Buy	+237	New	+$1.69K	﹤0.01%	1519
2017 Q2	–	Sell	-79	Closed	-$2K	–	2006
2017 Q1	$2K	Buy	+79	New	+$1.51K	﹤0.01%	1448

Other funds holding RARX

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Meeder Asset Management's RARX Position: Q4 2019 in Review

Meeder Asset Management sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q4 2019, closing a stake of 6,209 shares — an estimated $147K sold.

Meeder Asset Management first reported a position in RARX in Q1 2017 and held it in 7 quarters. The position peaked at $147K in Q3 2019. 146 funds tracked by Wall St. Rank hold RARX as of Q4 2019.

Meeder Asset Management reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
Meeder Asset Management sold 6,209 Ra Pharmaceuticals, Inc. Common Stock shares in Q4 2019, an estimated $147K.
Meeder Asset Management first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q1 2017 and held it in 7 quarters.
Meeder Asset Management's Ra Pharmaceuticals, Inc. Common Stock position peaked at $147K in Q3 2019.
146 funds tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q4 2019.

Based on Meeder Asset Management's 13F filing for Q4 2019, filed 13 Feb 2020.